<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664244</url>
  </required_header>
  <id_info>
    <org_study_id>CC-NIMO1</org_study_id>
    <nct_id>NCT04664244</nct_id>
  </id_info>
  <brief_title>Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma</brief_title>
  <official_title>Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor&#xD;
      prognosis. For eligible patients, radiotherapy remains the choice, which has the most&#xD;
      effective impact on the survival periods. On the hand, anti-angiogenic therapy has been&#xD;
      proved to be promising treatment for recurrent or advanced cervical carcinomas. This study&#xD;
      aims to discover the objective response of combination therapy with nimotuzumab (an&#xD;
      anti-epidermal growth factor receptor [EGFR] IgG1 humanized monoclonal antibody) and&#xD;
      radiotherapy in recurrent or metastatic uterine cervical squamous carcinoma in a single-arm,&#xD;
      open, phase 2 clinical trial. The primary endpoint is the objective response rate evaluated&#xD;
      by imaging methods. The second endpoints are the progression-free survival and overall&#xD;
      survival. The treatment toxicity is regarded as one the second endpoint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All eligible patients will undergo the same treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 years</time_frame>
    <description>The objective response rate includes complete and partial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival from the end of radiotherapy to the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival from the start of radiotherapy to the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
    <description>The rates of complete and partial remission, and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>3 years</time_frame>
    <description>The rates of adverse events judged by Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Recurrent Cervical Carcinoma</condition>
  <condition>Radiotherapy</condition>
  <condition>Epidermal Growth Factor Receptor</condition>
  <condition>Nimotuzumab</condition>
  <condition>Objective Response Rate</condition>
  <condition>Progression-free Survival</condition>
  <condition>Overall Survival</condition>
  <arm_group>
    <arm_group_label>All eligible patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combination of nimotuzumab and radiotherapy</intervention_name>
    <description>Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.</description>
    <arm_group_label>All eligible patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged more than 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score 0-1&#xD;
&#xD;
          -  Pathological confirmed of uterine cervical squamous carcinoma&#xD;
&#xD;
          -  An interval of 3 months or more since the fulfilling of last treatment&#xD;
&#xD;
          -  At least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) guideline 1.1&#xD;
&#xD;
          -  Anticipative survival period of 3 months or more&#xD;
&#xD;
          -  Lab testing within reference ranges&#xD;
&#xD;
          -  With appropriate contraception&#xD;
&#xD;
          -  Provided consents of participating the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With a history of exposure to other antiangiogenic agents&#xD;
&#xD;
          -  With other malignancies within past 3 years&#xD;
&#xD;
          -  With vital complications&#xD;
&#xD;
          -  With uncontrolled hypertension despite of medical treatment&#xD;
&#xD;
          -  With brain metastasis&#xD;
&#xD;
          -  With addiction to psychiatric medications or with mental disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D</last_name>
    <phone>86-139-1198-8831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>86-138-1022-4549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

